Skip to main content
  • Poster presentation
  • Open access
  • Published:

Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog

Background

The novel chimeric natriuretic peptide, CD-NP, is a Mayo-designed cGMP-activating synthetic peptide that consists of the 22-amino-acid (AA) residues of C-type natriuretic peptide (CNP) and the 15-AA C-terminal extension of Dendroaspis natriuretic peptide (DNP) [1]. The rationale for the design of CD-NP was to transform CNP, which activates natriuretic peptide receptor-B (NPR-B) and is natriuretic, diuretic and less hypotensive than ANP and BNP which activate NPR-A into a CNP-like peptide with added renal actions. The goal of this investigation was to directly compare the cardiorenal profile of CD-NP to that of CNP.

Materials and methods

Normal anesthetized dogs were given CD-NP 50 ng/kg/min i.v. (n = 10) or an equimolar dose of CNP (29.3 ng/kg/min i.v., n = 7) for 75 min. Four 30-min clearances were performed at the following time points: pre-infusion (pre-I), at 30 and 60 min of I, and post-I. Blood and urine samples were collected for each clearance. Glomerular filtration rate was determined by inulin clearance. Comparisons were made within group vs pre-I (mean ± SEM, P < 0.05*, <0.01†) and between groups (P < 0.05‡, <0.01§, <0.001) using repeated measures ANOVA.

Results

CD-NP significantly increased plasma cGMP (7 ± .4 to 25 ± 3† to 36 ± 3† to 23 ± 3† pmol/ml) and urinary cGMP excretion (978 ± 145 to 3170 ± 205†‡ to 5919 ± 616† to 3077 ± 298† pmol/min) versus CNP (7.8 ± .8 to 9.1 ± .3 to 10.1 ± .6† to 8.1 ± .6 pmol/ml; 1099 ± 101 to 1193 ± 119 to 1301 ± 142 to 1003 ± 146 pmol/min, respectively). CD-NP significantly increased urinary sodium excretion (19 ± 4 to 168 ± 24†§ to 237 ± 26† to 96 ± 12† μeq/min) versus CNP (39 ± 14 to 68 ± 12 to 85 ± 31 to 81 ± 29 μeq/min). Urine flow (ml/min) was augmented by CD-NP (0.2 ± .06 to 1.3 ± .2† to 1.8 ± .3† to 0.8 ± .2†) and CNP (0.5 ± .1 to 1.0 ± .2 to 1.3 ± .3* to 1.0 ± .3). Glomerular filtration rate was enhanced by CD-NP (37 ± 2*‡ to 48 ± 3† to 51 ± 3† to 53 ± 4† ml/min) and was preserved by CNP (55 ± 5 to 57 ± 6 to 52 ± 4 to 50 ± 6 ml/min). Pulmonary capillary wedge pressure was significantly reduced by CD-NP (5.7 ± .7 to 4.1 ± 1* to 3.2 ± .7†‡ to 4.3 ± .8 mmHg), but not by CNP (5.8 ± .7 to 5.7 ± .8 to 6.7 ± .7 to 7.4 ± .9† mmHg). Right atrial pressure was significantly reduced by CD-NP (1.8 ± .4 to 1.1 ± .4† to 0.9 ± .5†§ to 1.3 ± .5 mmHg), but not by CNP (2.7 ± .3 to 2.6 ± .3 to 3.2 ± .3 to 3.9 ± .4† mmHg). Neither CD-NP nor CNP induced systemic hypotension (mean arterial pressure 127 ± 4 to 124 ± 5 to 122 ± 6 to 126 ± 7 mmHg; 121 ± 5 to 126 ± 4 to 127 ± 5 to 126 ± 4 mmHg, respectively).

Conclusion

This study demonstrates the successful transformation of CNP to a CNP-like peptide, which is cGMP-activating, natriuretic, diuretic, GFR-enhancing, and cardiac unloading, and has minimal blood pressure lowering effects. This cardiorenal profile of CD-NP is highly attractive as a drug for the treatment of acute decompensated heart failure, warranting further investigation.

References

  1. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC: Design, synthesis and unique biological actions of CD-NP: A novel CNP-like chimeric natriuretic peptide [abst]. Circulation. 2006, 114 (18 Suppl II): II-440-

    Google Scholar 

Download references

Acknowledgements

Supported by the National Institutes of Health (HL36634; PO1 HL76611 and HL80732), the Mayo Foundation, and the Canadian Institutes of Health Research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Candace YW Lee.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Lee, C.Y., Boerrigter, G., Harty, G.J. et al. Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog. BMC Pharmacol 7 (Suppl 1), P37 (2007). https://doi.org/10.1186/1471-2210-7-S1-P37

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1471-2210-7-S1-P37

Keywords